fbpx

Chronic Lymphocytic Leukemia

Hem/Onc Roundup: ASCO Highlights, Plus Racial Disparities in Symptom Reporting

This week on DocWire, findings from CARTITUDE-1 found that ciltacabtagene autoleucel (cilta-cel), an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell...
Woman doctor using tablet computer in hospital

Analysis of Testing and Treatment Pattern Information Obtained from informCLL Registry

A poster presented during the Oncology Nursing Society (ONS) Congress highlighted information collected from informCLL, a prospective, observational, U.S.-based registry of patients with chronic...
Telemedicine concept. Group of young doctors having online conference in clinic

Online Education Beneficial Tool in Expanding Nurses’ Knowledge of Treatment-Naive CLL

There have been recent advancements in the frontline treatment of chronic lymphocytic leukemia (CLL), increasing the need for education regarding available therapies. A study...

Vitamin D Levels Are Often Low in Patients with Multiple Myeloma

Many patients with newly diagnosed multiple myeloma (MM), non-Hodgkin lymphoma/diffuse large B-cell lymphoma (NHL-DLBCL), and chronic lymphocytic leukemia (CLL) have low vitamin D levels,...
FDA Stamp

FDA Approves Imbruvica® Plus Rituxan® Combo to Treat CLL/SLL Through International Pathway

The U.S. Food and Drug Administration (FDA) approved Imbruvica® (ibrutinib) in combination with Rituxan® (rituximab) for the initial treatment of adult patients with chronic...

CAR T-Cell Therapy Induces Response in NHL and CLL

An anti-CD19 chimeric antigen receptor (CAR) T-cell-transduced natural killer (NK) therapy induced responses in patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL),...

Clinical Trial Participants vs. Medicare Beneficiaries Receiving Idelalisib: An Outcomes Analysis

A new study compared outcomes between relapsed follicular lymphoma and relapsed chronic lymphocytic leukemia patients treated with idelalisib in the clinical setting versus clinical...
FDA approved stamp

FDA Approves Second Drug Under New International Network Pathway for CLL/SLL

The U.S. Food and Drug Administration (FDA) granted supplemental approval to Calquence® (acalabrutinib) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The...

Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do...

Human leukocyte antigen B27 (HLA-B27), associated with spondyloarthritis, was suggested to be protective against chronic lymphocytic leukemia (CLL). It is hypothesized that HLA-B27 patients may have...
Combo Ibrutinib plus Venetoclax Treatment Effective in Relapsed CLL

Combo Ibrutinib plus Venetoclax Treatment Effective in Relapsed CLL

A study published in the Oct. 20 issue of the Journal of Clinical Oncology examined the effects of combination ibrutinib plus venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

PURPOSE: The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly...